Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) shares were down 6% during mid-day trading on Friday . The stock traded as low as $13.26 and last traded at $13.26. Approximately 2,863 shares were traded during trading, a decline of 98% from the average daily volume of 185,281 shares. The stock had previously closed at $14.11.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on SION shares. Stifel Nicolaus started coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They set a "buy" rating and a $32.00 target price on the stock. Guggenheim initiated coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating and a $45.00 price objective on the stock. TD Cowen initiated coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating on the stock. Finally, Wall Street Zen lowered Sionna Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd.
Read Our Latest Analysis on Sionna Therapeutics
Sionna Therapeutics Stock Down 0.8%
The stock's 50 day moving average price is $11.74.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.17).
Hedge Funds Weigh In On Sionna Therapeutics
Several large investors have recently bought and sold shares of SION. Jennison Associates LLC bought a new position in Sionna Therapeutics in the first quarter valued at about $8,995,000. TD Asset Management Inc bought a new position in Sionna Therapeutics in the first quarter valued at about $579,000. Charles Schwab Investment Management Inc. bought a new position in Sionna Therapeutics in the first quarter valued at about $676,000. CenterBook Partners LP bought a new position in Sionna Therapeutics in the first quarter valued at about $1,195,000. Finally, Aberdeen Group plc bought a new position in Sionna Therapeutics in the first quarter valued at about $7,803,000.
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
See Also
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
